



---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 29, 2010**

**UROPLASTY, INC.**

(Exact name of registrant as specified in charter)

**001-32632**  
(Commission File No.)

**41-1719250**  
(IRS Employer Identification No.)

**Minnesota**  
(State or other jurisdiction of incorporation or organization)

**5420 Feltl Road**  
**Minnetonka, Minnesota 55343**  
(Address of principal executive offices)

**952-426-6140**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name and Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 of the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



---

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

*Transfer of Listing*

On June 29, 2010, we received a letter from the NASDAQ Stock Market LLC (“NASDAQ”) approving our application to list our common stock on the NASDAQ Capital Market. On June 18, 2010, our Board of Directors authorized the officers of our company to apply for the listing of our common stock on NASDAQ and withdraw the listing of our common stock from the NYSE Amex stock exchange (the “NYSE Amex”). We provided NYSE Amex written notice on June 29, 2010 of our intention to withdraw the listing of our common stock from NYSE Amex. We expect that our common stock will begin trading on the NASDAQ Capital Market under the symbol “UPI” on July 12, 2010. Our common stock will continue to trade on NYSE Amex until the market close on July 9, 2010.

A copy of the press release announcing the delisting of our common stock from NYSE Amex and the listing of our common stock on the NASDAQ Capital Market is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibit (filed herewith)

99.1 Press Release dated June 29, 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 30, 2010

UROPLASTY, INC.

By: /s/ Mahedi A. Jiwani  
Mahedi A. Jiwani  
Vice President, Chief Financial  
Officer and Treasurer



<DOCUMENT>  
<TYPE> EX-99.1  
<FILENAME> c58905exv99w1.htm  
<DESCRIPTION> EX-99.1  
<TEXT>

Exhibit 99.1

NEWS RELEASE



**Uroplasty, Inc. to begin trading on NASDAQ Capital Markets**

**MINNEAPOLIS, MN, June 29, 2010** – Uroplasty, Inc. (NYSE AMEX: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that it has been approved for listing on the NASDAQ Capital Market under the symbol “UPI.”

Trading on the NASDAQ Capital Market is expected to commence on July 12, 2010. The Company’s common stock will continue to trade on AMEX until the market close on July 9, 2010.

“We are pleased to announce the Company’s listing on the NASDAQ Capital Market,” commented David Kaysen, President and Chief Executive Officer. “We believe the move to NASDAQ will improve the visibility of our stock, enhance trading liquidity in our shares, and provide the Company with greater exposure to institutional investors.”

**About Uroplasty, Inc.**

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent PC® System, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence — symptoms often associated with overactive bladder. We also offer Macroplastique®, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at <http://uroplasty.com>.

**Forward-Looking Information**

This press release contains forward-looking statements. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

[E/O]

CRC: 62210  
EDGAR 2

BOC C58905 799.01.02.00 0/1  


---

**For Further Information:**

Uroplasty, Inc.  
David Kaysen, President and CEO, or  
Medi Jiwani, Vice President, CFO, and Treasurer,  
952.426.6140

EVC Group  
Doug Sherk (Investors)  
415.896.6820  
Chris Gale (Media)  
646.201.5431

###